Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01143766 · ClinicalTrials.gov registry record · NA
Gabapentin to Improve Patient Tolerance in Endoscopic Retrograde Cholangiopancreatography (ERCP)
A NA study, sponsored by Indiana University.
- Completed
- Registry status
- NA
- Development phase
- 56
- Enrollment target
NCT01143766 is a NA study that has completed, run by Indiana University. The registered enrollment target is 56 participants.
The verdict
NCT01143766, a NA study, has completed, sponsored by Indiana University.
- COMPLETED
- Registry status
- NA
- Development phase
- 56 participants
- Enrollment target
Study Summary
The standard approach to sedation in endoscopic retrograde cholangiopancreatography (ERCP) involves the use of benzodiazepines and opiates to achieve a moderate depth of sedation. There is data to suggest supplementing this regimen with gabapentin may lead to reduced pain, higher patient satisfaction and lower opiate requirements. The investigators are conducting a clinical trial to study this hypothesis.
Interventions
- DRUG Gabapentin
- OTHER Standard sedation regimen
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 56 participants |
| Start Date | 2010-04 |
| Est. Completion | 2011-12 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01143766
The ClinicalTrials.gov registry entry for NCT01143766 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 56 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Indiana University, which has 890 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Gabapentin is the first listed.
NCT01143766 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01143766 about?
NCT01143766 is a clinical study titled "Gabapentin to Improve Patient Tolerance in Endoscopic Retrograde Cholangiopancreatography (ERCP)". The standard approach to sedation in endoscopic retrograde cholangiopancreatography (ERCP) involves the use of benzodiazepines and opiates to achieve a moderate depth of sedation. There is data to suggest supplementing this regimen with gabapentin may lead to reduced pain, higher patient satisfactio...
What is the current status of trial NCT01143766?
This trial is currently completed. It is a NA study. The enrollment target is 56 participants. The study started on 2010-04. Estimated completion is 2011-12.
What interventions are being tested in trial NCT01143766?
The interventions under investigation include: Gabapentin (DRUG), Standard sedation regimen (OTHER).
Who is sponsoring clinical trial NCT01143766?
This trial is sponsored by Indiana University, which has 890 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.